Nanopatch to help WHO battle polio

The World Health Organisation's (WHO) battle against polio has a new weapon after joining forces with Vaxxas, the biotechnology company responsible for developing revolutionary vaccine delivery method the Nanopatch.

WHO will undertake a research collaboration with Vaxxas, a start-up company that spun out from The University of Queensland.

The collaboration will evaluate Nanopatch's use as a platform for delivery of and WHO may subsequently elect to fund clinical demonstrations.

The Nanopatch was invented at UQ's Australian Institute for Bioengineering and Nanotechnology (AIBN) by Professor Mark Kendall, and aims to replace traditional needle and syringe methods with a small patch.

It features thousands of small projections designed to deliver the painlessly to the skin.

"We are delighted to be collaborating with WHO, applying the Nanopatch to help deliver effective polio vaccines to the areas that need them most," said Professor Kendall, Vaxxas Founder and Chief Technology Officer.

"This project helps realise key advantages of the Nanopatch over the needle and syringe. While the traditional needle and syringe delivers the vaccine to the muscle, the Nanopatch targets the abundant immune cells under the skin, increasing its effectiveness.

"Furthermore, the Nanopatch doesn't need to be kept refrigerated to maintain its efficacy. These advantages – together with a simple, needle-free administration – open a way to effective transportation and application of polio vaccine in the remote regions of the world where eradication efforts are most challenging."

Phases of this project will be conducted within Professor Kendall's UQ research group with project drivers including postdoctoral research fellow Dr David Muller.

Following clinical development, Vaxxas would have the opportunity to supply Nanopatches in support of WHO's global polio eradication efforts.

More information:

Citation: Nanopatch to help WHO battle polio (2014, September 17) retrieved 28 February 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Merck partnership accelerates needle-free vaccine delivery


Feedback to editors